Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 8, 2003

Primary Completion Date

December 11, 2018

Study Completion Date

December 14, 2018

Conditions

Severe Hemophilia A

Interventions

DRUG

Alphanate SD/HT

Plasma-derived preparation of Factor VIII

Trial Locations (2)

Oddzial Chorob Wewnetrznych i Hematologii, Poznan

Katedra i Klinika Hematologii Collegium Medicum UJ, Krakow

All Listed Sponsors

lead

Grifols Biologicals, LLC

INDUSTRY

NCT00323856 - Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A | Biotech Hunter | Biotech Hunter